Research programme: antibodies to infectious agents - Affitech

Drug Profile

Research programme: antibodies to infectious agents - Affitech

Latest Information Update: 18 Jan 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Affitech AS
  • Class Antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Meningococcal infections; Varicella zoster virus infections

Most Recent Events

  • 17 Aug 2005 This programme is still in active development - (BIO-2005)
  • 28 Jun 2004 Varicella zoster virus and Neisseria meningitides antibody products are available for licensing (http://www.affitech.com)
  • 28 Jun 2004 Preclinical trials in Meningococcal infections in Norway (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top